OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax(TM) in China and Ukraine

BATON ROUGE, LA--(Marketwired - November 10, 2015) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces that the Company has received Notices of Allowance for patents on ProscaVax™, OncBioMune's cancer vaccine nearing completion of a Phase 1 trial for prostate cancer, from the State Intellectual Property Office (SIPO) of the People's Republic of China (PRC) and the State Enterprise "Ukrainian Institute of Industrial Property" (Ukrainian Patent Office).

The patents, titled "Composition and Method for Treating Cancer" -- Appln, No. 201080005114.4 (PRC) and Appln. No. A 2013 09855 (Ukraine) - add to the intellectual property of ProscaVax™ and protect the vaccine through 2031. A previous patent for ProscaVax™ has been granted in the United States (U.S. Patent 8,647,627), and another related U.S. Patent application has recently received a Notice of Allowance (U.S. application 14/137,060).

"We are very pleased with the allowance of the patents to extend protection of ProscaVax™ as a novel cancer vaccine," commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. "Cancer rates soaring in China present a true health emergency and the number of cancer patients in the Ukraine now exceeds one million. We hope that one day ProscaVax™ will be able to provide a viable solution in these regions with a great need for innovative new cancer therapies."

About OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary Vaccine Technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient. Our lead product, ProscaVax™ is scheduled to commence a Phase 2 clinical study in early 2016. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceutical's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals' need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical's vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.